Consultant Senior Lecturer in Movement Disorders Neurology at the University of Bristol & Honorary Consultant Neurologist at North Bristol Trust, UK. Alan Whone leads a regional movement disorders clinical service at the Bristol Brain Centre that conducts approximately 4000 people with Parkinson’s reviews per year from the diagnostic to the palliative stage. This service includes one of the largest deep brain stimulation surgery programmes for movement disorders in the UK, performing over 60 new implantations per annum. Alan’s PhD research employed Positron Emission Tomography to assess rates of progression in people with early Parkinson’s randomised to L-dopa or the dopamine agonist Ropinirole (Ann Neurol. 2003). The REAL-PET study is in the canon of controversial trials in Parkinson’s but nevertheless sparked Alan’s interest in disease modification in Parkinson’s disease. From late 2011 to early 2017 he was chief investigator of two single-centre academic-led studies assessing the efficacy of Glial Cell Line-Derived Neurotrophic Factor (GDNF) in Parkinson’s. These investigations employed a novel mechanism of administration, involving a skull-mounted port, to achieve intraputaminal convection-enhanced delivery (CED) of study-drug on a monthly basis. The studies reported in Brain and the Journal of Parkinson’s in 2019 disease raise important questions on where next for neurorestorative therapies in Parkinson’s.